Twenty people in Japan who took an Amgen (AMGN) rare immune-disease drug have died, according to the company that sells the Medicine in Japan; US drug regulators had asked Amgen to voluntarily withdraw the drug

The report of twenty deaths linked to Amgen's rare immune-disease drug in Japan raises significant concerns about regulatory scrutiny and public safety, prompting US drug regulators to recommend a voluntary withdrawal of the medication. This development could lead to increased volatility in Amgen's stock and broader implications for the biotech sector as market participants reassess the risk profile of pharmaceutical investments. Additionally, this may spill over into commodities, especially if fears about regulatory crackdowns heighten investor caution around healthcare stocks and related sectors.